Navigation Links
Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics' Human Pilot Study

RENSSELAER, N.Y., Dec. 13, 2012 /PRNewswire-iReach/ -- Ultradian Diagnostics LLC, an early-stage medical device company based in Rensselaer, New York, today announced the publication of clinical study results for Biologue, the Company's minimally invasive continuous glucose monitoring (CGM) system, in the November 2012 issue of the Journal of Diabetes Science and Technology. In the peer-reviewed article entitled "Pilot Study of a Prototype Minimally Invasive Intradermal Continuous Glucose Monitor," the authors report the Biologue provided clinically accurate results 98.9% of the time and was well tolerated by study participants, with no pain and no adverse events observed. The study was funded in part by a National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Business Catalyst grant and conducted by investigators from the State University of New York Upstate Medical University and Ultradian Diagnostics.

The study demonstrated clinical proof of concept for Ultradian's Biologue CGM using a proprietary single point calibration method and unique biofouling correction algorithm. "We believe this publication validates our novel approach to improved accuracy and methods to mitigate the in vivo effects of sensor biofouling," said Dr. John Willis, CEO of Ultradian Diagnostics. "The accuracy and tolerance data from this pilot study is very positive and represents a significant milestone on our path to develop a user calibration-free CGM capable of interfacing with an insulin pump to form the long-sought, closed-loop Artificial Pancreas."

The full article is available on the Journal of Diabetes Science and Technology website: (

About Ultradian Diagnostics

Ultradian is a medical device company developing continuous, wireless, wearable biosensors for monitoring chronic illnesses. The Company was founded to improve the accuracy of minimally invasive biosensors so they may be used at the bedside in hospitals and by people for self-monitoring of chronic illnesses. Ultradian's initial product, called Biologue, is a minimally invasive biosensor system that continuously measures glucose within the skin. Biologue is a platform technology where components of the core system can be leveraged into other product opportunities. Ultradian is actively seeking strategic partners to accelerate commercial introduction of their continuous monitoring technologies. For more information about Ultradian Diagnostics, please visit

Media Contact: John P. Willis, CEO Ultradian Diagnostics LLC, 518-312-7852,

News distributed by PR Newswire iReach:


SOURCE Ultradian Diagnostics LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Bio Implements Major Balance Sheet Clean-Up
2. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
3. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
4. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
5. Research could lead to new drugs for major diseases
6. APCER Pharma Sponsors Major Industry Conference
7. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
8. Promotion of Young Researchers Supported by Major Donation
9. Kitty Castellini Wins Roche Diabetes Cares Diabetes Heroes Torchbearer Challenge
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
Post Your Comments:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... , ... October 09, 2017 , ... ... four-tiered line of medical marijuana products targeting the needs of consumers who are ... of Kindred takes place in Phoenix, Arizona. , As operators of two successful ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):